



*EMERGENCY IN THE EMERGENCY DEPARTMENT*




What do an ER nurse and an NFL quarterback have in common?



They both have the most dangerous jobs in America



# Problem: Violence in Healthcare is an Epidemic



- Nearly 50% of emergency physicians and 70% of ER nurses report being assaulted
- 25% of psychiatric nurses experience disabling injuries from patient assaults

*"Every minute these patients are agitated poses significant harm to both hospital staff and patients - Dr. Becky Smith, Salisbury, N.C."*



**MOST DANGEROUS WORKPLACE** - ER nurses are 5X more likely to suffer patient-induced injuries compared to any other major industry and it's increasing



**UNMET CLINICAL NEED** -There have been no new drugs or delivery improvements of existing products in over 30 years that could mitigate the injury risk and costs



**VIOLENCE COST HOSPITALS \$6 BILLION** in 2016, motivating them to find ways to reduce attacks, turnover, and costs associated with treating violent patients



**NOT LIKE THE MOVIES** - The onset of sedation for current products is extremely variable, 10 to 60 minutes

# Faster and more reliable sedative – Why?

Because treating violent patients affects everyone



## IT'S ALL HANDS ON DECK

Requires multiple staff until the patient is calm

Doctors' and nurses' attention is diverted away from other patients

Results in longer wait times for new patients to see a doctor

60% of doctors surveyed say patients have left before receiving treatment


The goal is to restore the regular ER routine as quickly as possible




Emergency  
in the  
Emergency  
Department

# Improving IM Sedation of Agitated and Violent Patients


## Proviza Injection (Avizafone dihydrochloride)



### Time to Peak Blood Level (median and range)



### Proviza - The first drug in its class targeting faster sedation in over 30 years




### Proviza aims to:


- Reduce the significant variation in sedation time for current drugs
- Decrease injury risk to the ER staff
- Provide a significant reduction in hospital costs resulting from treating violent and aggressive patients

# Market Size

## Two Addressable Markets: Acute Agitation and Seizure Emergencies




### Global Market Growth Rate




# Market Acceptance

## Acute Agitation and Aggression




### Percent of physicians likely to prescribe Proviza




### Survey Results: Proviza will Disrupt the Prescribing Patterns of Drugs Use to Treat Acute Agitation and Aggression

Before Proviza



After Proviza is available




**Proviza is poised to take a significant share from the market leader - lorazepam**



# Timeline to NDA Submission and Cost

## Proviza (Avizafone Injection) Timeline Scale Up After Results of the First Clinical




# Financial Projections



## Forecast Assumptions:

- Launch in the US and top 3 EU Countries
- Low penetration in the seizure market
- Sales through distribution and marketing partner



# Achieving Non-dilutive Funding

- Violence in the Emergency Department is an international public health crisis
- IM delivery of current products to obese and severely obese patients can be erratic. Proviza will improve delivery to this population of patients.
- Non-dilutive funding opportunities are available to support Proviza's development through NIH and SBA grants.



## Convertible Note Financing up to \$300,000 To Support the Acquisition of Non-dilutive Funding

### Use of Funds:

- Advances development of Proviza Injection for rapid sedation
- Submission of multiple non-dilutive grant applications to support the study of Proviza in the entire general population
- Preparation for an FDA pre-IND meeting



# Sollievo Pharmaceuticals, Inc.

- Founded in 2018
- California C-corp
- Located in San Juan Capistrano, CA

## *What we do*

*Through modification of existing drugs, we produce solutions to unmet medical needs.*



## The Team



**Robert Schultz, Ph.D.**  
Founder and CEO

Dr. Schultz has held various Scientific and Executive Management positions during his 40-year career in the pharmaceutical and medical device industries. His expertise in the development of combination products and ability to lead internal and external resources in the start-up environment provides Sollievo with the leadership to successfully navigate the drug development process.



**Paul Waymack, M.D., Sc.D.**  
Regulatory and Clinical

Dr. Waymack is a regulatory consultant, and previously worked as an FDA medical reviewer and special consulting reviewer, responsible for assessing new drug applications and investigational drug applications. Both his consulting and chief medical officer experience with early-stage companies will strengthen the management team in all activities pertaining to the development of Proviza, including regulatory and clinical activities.



**Peter Schineller**  
Commercial Strategy Advisor

During his 35-year career, Mr. Schineller has held SVP and Chief Commercial Roles at leading drug and diagnostic companies and founded his own start-up Veras Pharmaceuticals., where he was the CCO. Mr. Schineller's role is to guide the company to a marketing and launch strategy that will ensure successful uptake of Proviza post-launch.



**Steve King, BPharm**  
Business Development

Experienced Senior Manager with a 30-year history of working in the Pharmaceutical industry. Strong professional skills in Business Development, Alliance Management, Licensing, CMC Outsourcing, Biotechnology, Drug Development, and Pharmaceutical Project Management. Steve is responsible for identifying, sourcing, and contract negotiations with potential manufacturing partners and suppliers.




Proviza<sup>®</sup>

*Improving Intramuscular Sedation in the  
Emergency Setting*

**Contact:**

**Robert K. Schultz, Ph.D.**

 [schultz@sollievopharm.com](mailto:schultz@sollievopharm.com)

 +1 858 243 0417